Cover Story

Type 2 diabetes (T2D) is a chronic, debilitating disease with major social, fiscal, and medical costs. The prevalence of this disease is increasing markedly, and, despite the emergence of new therapies targeting insulin secretion, insulin action and/or glucose excretion, glycemic control remains generally sub-optimal, emphasizing the continued need for new therapeutic options.

The obesity medication lorcaserin, a 5-hydroxytryptamine 2C receptor (5-HT2CR) agonist, improves glycemic control in association with weight loss in obese patients with T2D. Burke and colleagues find that lorcaserin improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body weight. Examining the mechanism of this effect, they reveal a necessary and sufficient neurochemical mediator of lorcaserin’s glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin’s therapeutic brain circuit, they examined the receptor target of POMC peptides. Burke et al. demonstrate that lorcaserin requires functional melanocortin 4 receptors on cholinergic preganglionic neurons to exert its effects on glucose homeostasis.

There is growing interest in brain control of peripheral glycemia and the potential for targeting the arcuate nucleus of the hypothalamus for therapy in T2D. The authors suggest that lorcaserin should be investigated in patients with T2D for blood glucose lowering therapy, in addition to its already approved licensing for body weight reduction

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.



Amna Khamis
University of Lille, CNRS, Institute Pasteur de Lille, Lille, France
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at www.sciencedirect.com/journal/molecular-metabolism
Conferences & Events
June 30 −
July 1
2019
ATLAS Symposium 2019
Middelfart, Denmark
August
25 − 30
2019
Epigenomics, Nuclear Receptors and Disease
Spetses Island, Greece
September
9 − 12
2019
Ageing and Regeneration
Innsbruck, Austria
September
23 − 25
2019
7th Helmholtz Diabetes Conference
Munich, Germany
October
15 − 18
2019
Nature Conference: Advances in Metabolic Communication
Rio de Janeiro, Brasil
October
15 − 18
2019
13th European Nutrition Conference
Dublin, Ireland
October
27 − 31
2019
Metabolism in Action
Hillerod, Denmark
December
6 − 8
2019
Cachexia, Sarcopenia and Muscle Wasting
Berlin, Germany
Media Coverage
Supported by